Cloud-Clone’s 14 Antibodies Support New Rheumatoid Arthritis Therapy Mechanism Published in ACS Nano

Multifunctional Methotrexate-Loaded Nanotherapeutics Modulate the Joint-Brain Axis and Mitigate Peripheral Joint Damage as well as Central Neuroinflammation

HUSTON, TX, UNITED STATES, November 11, 2026 /EINPresswire.com/ — In September 2026, a collaborative research team from the Institute of Nano Science and Technology, India, and Jeju National University, Republic of Korea, published their groundbreaking work in ACS Nano. The research uncovers the dual-action therapeutic potential of methotrexate-loaded nanomicelles for rheumatoid arthritis (RA), addressing both joint destruction and RA-triggered neuroinflammation. A total of 14 research antibodies manufactured by Cloud-Clone served as core analytical reagents throughout this investigation, enabling reliable biomarker detection and robust mechanistic interpretation for the whole study.
Rheumatoid arthritis represents a chronic autoimmune disorder characterized by progressive joint degeneration, systemic inflammation and eventual functional disability. Its pathogenesis arises from a complex interplay of genetic predisposition, hormonal changes, microbial influences, metal exposure and immune dysregulation. Current therapeutic options including non-steroidal anti-inflammatory drugs, corticosteroids and conventional anti-rheumatic agents can relieve clinical symptoms and slow joint deterioration, yet they are constrained by low bioavailability, severe systemic adverse effects and limited overall therapeutic outcomes.
Driven by an extensive network of pro-inflammatory mediators, RA fuels immune cell recruitment, synovial inflammation and subsequent cartilage erosion. Beyond peripheral joint lesions, systemic inflammation can propagate to the central nervous system and induce neuroinflammation, further resulting in cognitive impairment and mood disturbances. Conventional therapeutic modalities rarely target peripheral joint pathology and central nervous system complications simultaneously, creating an urgent demand for integrated treatment strategies that suppress local inflammation while alleviating secondary neuronal impairments. Cloud-Clone has long focused on inflammatory-factor-oriented research and develops comprehensive panels of monoclonal and polyclonal antibodies across multiple species to meet such cutting-edge research requirements.
Nanomicelle systems facilitate the targeted delivery of hydrophobic potent therapeutics toward inflamed tissues, enhancing therapeutic efficacy while minimizing off-target systemic toxicity. In this project, researchers constructed tryptophan-PLGA-glutathione nanomicelles loaded with methotrexate (M-WPG NMs), and systematically evaluated their capacity to ameliorate joint inflammation and reverse RA-associated neurocognitive deficits. In vitro assays demonstrated that M-WPG NMs mitigate microglia-driven neuroinflammation by boosting intracellular methotrexate delivery and scavenging reactive oxygen species. In vivo tests using collagen-induced arthritis (CIA) rat models revealed remarkable attenuation of paw erythema and swelling in the M-WPG NMs-treated cohort, outperforming comparator groups. Diverse target-specific antibodies supplied by Cloud-Clone delivered dependable biomarker profiling for therapeutic efficacy assessment.

Figure 1 Representative photographs of rat hind paws from healthy control, CIA arthritis model and different treatment groups
Histological assessments confirmed superior cartilage preservation in animals receiving M-WPG NMs, compared with free methotrexate and drug-free B-WPG NMs groups. To dissect the underlying anti-inflammatory mechanisms, researchers performed immunohistochemical (IHC) staining on joint tissue sections utilizing Cloud-Clone antibodies. These reagents targeted a broad spectrum of molecules linked to inflammation, osteoclastic bone resorption, cartilage breakdown, oxidative stress and inflammasome signaling. Markedly reduced expression of TNF-α and RANKL indicated dampened pro-inflammatory mediator production and inhibited osteoclast-activating signaling cascades. Down-regulated NF-κB and TLR-4 reflected suppression of upstream inflammatory initiation pathways. Decreased levels of neutrophil elastase, MMP-2, MMP-9, MMP-13 and iNOS pointed to relieved tissue degradation and oxidative stress. Diminished NLRP3 expression further suggested restrained IL-1β maturation and persistent chronic inflammation. Collectively, these findings illustrate that M-WPG NMs exert joint-protective effects via concurrent blockade of upstream and downstream inflammatory signaling cascades.

Figure 2 IHC profiling illustrates the expression landscape of key inflammatory and structural biomarkers within joint tissues
RA pathology extends past articular destruction and frequently gives rise to anxiety-like behaviors, depressive symptoms and compromised motor coordination. Behavioral characterizations showed that M-WPG NMs administration restored grip strength, lowered slip frequency, and largely normalized motor coordination in experimental rats. Subsequent IHC profiling of hippocampal and cortical brain tissues, conducted with Cloud-Clone antibodies, displayed lowered cerebral TNF-α and NF-κB abundance. M-WPG NMs treatment also rescued the diminished expression of Fibronectin, Beclin, Occludin and Claudin. The experimental evidence demonstrates that M-WPG NMs confer neuroprotective benefits by modulating the joint-brain axis, curbing pro-inflammatory and oxidative cascades, restoring blood-brain barrier-associated protein markers and triggering autophagy-dependent cellular repair.

Figure 3 IHC detection visualizes Occludin expression across distinct brain sub-regions

Comprehensive pre-clinical safety evaluation was implemented to verify systemic biocompatibility. Hematoxylin-eosin staining of major organs including heart, lung, liver, kidney and spleen detected no overt histological abnormalities across experimental cohorts, which was further corroborated by serum biochemical measurements. The research team concluded that M-WPG NMs constitute a promising targeted therapeutic platform for RA, delivering dual protection against joint deterioration and neurocognitive impairment through modulation of both peripheral and central inflammatory signaling. Antibodies from Cloud-Clone supported biomarker measurement in joint and cerebral tissues throughout the complete workflow covering efficacy validation, mechanistic exploration and safety profiling, generating reproducible and traceable experimental datasets for study conclusions.

The 14 Cloud-Clone antibodies deployed in this study supported in-vitro pharmacodynamic evaluation, joint-relevant mechanistic dissection and central nervous system biomarker quantification. Targets span TNF-α, RANKL, NLRP3, tight-junction proteins and numerous other critical biomarkers, covering research themes including inflammation, bone resorption, cartilage damage, oxidative stress, autophagy and blood-brain barrier biology. Cloud-Clone’s monoclonal and polyclonal reagents recognize target antigens stably across multiple species, supporting cross-species comparison and translational investigation. Researchers may select appropriate antibody formats flexibly according to experimental requirements, balancing high specificity and reliable sensitivity. This full reagent toolkit serves cellular assays, animal pathological examination, tissue immunostaining and cerebral biomarker measurement, covering the full research pipeline of efficacy evaluation, mechanistic exploration and safety assessment.
Publication in this high-impact international journal validates the dependable performance of Cloud-Clone antibodies for sophisticated high-level research applications. Concentrating on inflammatory factor research, Cloud-Clone develops integrated specialized reagent portfolios, delivering matched antibody solutions for rheumatoid arthritis, neuroinflammation, joint-brain axis and other interdisciplinary research fields. Premium-grade antibody products empower every stage of global scientific research.

For investigators exploring autoimmune arthritis, neuroinflammation and organ-axis cross-talk mechanisms, well-validated detection reagents are indispensable to translate conceptual hypotheses into publishable findings. Cloud-Clone keeps optimizing its antibody product portfolio, aiming to furnish global research communities with robust, versatile biomarker tools and accelerate progress in autoimmune disease translational research.
About Cloud-Clone Corp.
Cloud-Clone Corp. is dedicated to the development and production of high-quality immunoassay reagents and detection solutions. With a focus on antibody engineering, multiplex assay development, and cross-platform compatibility, the company provides research tools designed to support precision medicine and advanced biomedical investigation globally. Our core products and services include the research and development of proteins, antibodies, ELISA kits, primary cells, and multiplex cytokine assay kits, as well as professional CRO services to fully meet the diverse needs of biomedical research and related fields.
For more information about Cloud-Clone Corp, visit www.cloud-clone.com.

CLOUD-CLONE CORP.(CCC)
Tel: 001-832-538-0970, 0086-27-8425-9552
Email: mail@cloud-clone.com, sales@cloud-clone.us

Visit us on social media:
LinkedIn: https://www.linkedin.com/company/cloud-clone-corp/
Instagram: https://www.instagram.com/cloudclonecorp2023/
TickTok: https://www.tiktok.com/@cloudclonecorp2026

SuKi Duan
CLOUD-CLONE CORP.WUHAN
Visit us on social media:
LinkedIn
Instagram
TikTok
X

Media gallery